{"id":"W3207677309","doi":"10.1097/qad.0000000000003085","title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","year":2021,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Rilpivirine; Dosing; Medicine; Dolutegravir; Adverse effect; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Clinical endpoint; Clinical trial; Virology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001247849,0.0001299526,0.000298563,0.00007262477,0.00004153706,0.00002016013,0.0000351473,0.00005435307,0.0001252723],"category_scores_gemma":[0.00005397372,0.0001073187,0.00006918802,0.0001691177,0.00002299242,0.00006541115,0.00004677148,0.0000676817,0.00001157107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003133728,"about_ca_system_score_gemma":0.00007882516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001858053,"about_ca_topic_score_gemma":0.00001356712,"domain_scores_codex":[0.9991597,0.00002253136,0.000202884,0.0002492004,0.0001627528,0.0002029249],"domain_scores_gemma":[0.9994905,0.00006892219,0.00003968129,0.0001988482,0.00008579907,0.0001162229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001422734,0.0003469399,0.6592725,0.0001274007,0.0002998668,0.000428871,0.004141001,0.000004639724,0.01818735,0.00003672689,0.003218037,0.3125139],"study_design_scores_gemma":[0.009989643,0.0007454636,0.7256858,0.0007018372,0.0002490375,0.00005607692,0.0009681078,0.00007467057,0.1562272,0.0001090966,0.1047755,0.0004175486],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959964,0.0009869786,0.0004270765,0.001626195,0.0001087048,0.0003285935,0.00002136336,0.00002251942,0.0004821485],"genre_scores_gemma":[0.970611,0.00005434828,0.02218,0.0002769829,0.00007841133,0.00005511846,0.00006579552,0.00002564132,0.00665268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3120964,"threshold_uncertainty_score":0.437633,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0185377159993329,"score_gpt":0.2898791553787556,"score_spread":0.2713414393794227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}